SAN FRANCISCO--(BUSINESS WIRE)--Healthcare technology company Komodo Health today launches a new product, National Drug Projections, bringing its customers a clear, complete, and detailed view of how many prescriptions are filled across the country for any group of medications. The new solution unlocks real-time market landscape intelligence, such as prescription volume, units dispensed, and new patient starts, to deliver an in-depth understanding of treatment dynamics that can better inform revenue forecasts, market share tracking, marketing resourcing, salesforce sizing, and more.
For healthcare and Life Sciences teams, having a clear view of a company’s drug portfolio performance and future potential is essential to drive impactful brand strategies. Komodo’s new offering leverages a vast array of de-identified insights from the Healthcare Map™ – which is derived from Medicare claims, commercial claims, and health records from over 300 million individuals – to deliver a superior approach to answering important questions around measuring traditional prescription retail dispenses and tracking medical benefit infusions and procedures, prescription specialty products, and compound events.
National Drug Projections is the most comprehensive solution on the market, offering a view of both pharmacy benefit (retail and specialty) and medical benefit drugs – with brands, biosimilars, and generics grouped together or broken out – to swiftly compare medications side-by-side and identify opportunities in the market. With intelligence on more than 10,000 therapies, National Drug Projections allows users to build customized reports on drug trends and market share. Each report provides a transparent view of total projected vs. observed values, as well as confidence intervals.
“National Drug Projections delivers actionable intelligence and a precise view on market dynamics to help Life Sciences companies make smarter decisions,” said Paul Gurney, Senior Vice President of Data Product, Komodo Health. “With robust and up-to-date projections, companies can track competitive performance, proactively adjust their strategies, optimize resource allocation, and better navigate market uncertainties – ultimately helping maximize market share and drive growth in a fast-evolving landscape.”
Komodo’s new offering was designed to complement its Healthcare Map – the industry’s most robust and precise view of longitudinal de-identified patient-level insights – with access to projected variables that can help companies more accurately assess therapy volumes, track competitive landscapes in real-time, and develop reliable forecasts for market success.
National Drug Projections is available as a standalone product and can be integrated into Komodo’s MapLab platform, making it easily accessible across teams and functions. Users with any level of data expertise can select their drugs of interest and within minutes receive insights in a real time dashboard with multiple variables and visualizations. The new solution is the foundation for an evolving product suite, including future IC-grade, subnational, and indication-based projections, that Komodo Health will be launching over the coming months and into 2025.
About Komodo Health
Komodo Health is a technology platform company creating the new standard for real-world data and analytics by pairing the industry’s most complete view of patient encounters with artificial intelligence to connect the dots between individual patient journeys and large-scale health outcomes. Across Life Sciences, payers, providers, and developers, Komodo helps its customers unearth patient-centric insights at scale – marrying clinical data with advanced algorithms and AI-powered software solutions to inform decision-making, close gaps in care, address disease burden, and help enterprises create a more cost-effective, value-driven healthcare system. For more information, visit Komodohealth.com.
